Clinical tolerance and diagnostic efficacy of iobitridol 300 in lower limb angiography

The diagnostic efficacy and the clinical tolerance of iobitridol 300 was evaluated in 68 patients receiving intraarterial injection in 2 monocentric comparative randomized double-blind trials with iopromide 300 (30 patients) and iopamidol 300 (40 patients) as reference. RESULTS; There is no significant difference in quality of opacification or in diagnostic efficacy between the products in each trial. No major adverse reactions occurred after the injection of iobitridol 300. Excluding a heat sensation, 5 of the patients who received iobitridol had minor reactions consisting of nausea with vomiting and pain during the injection. Five patients in the reference group also experienced adverse events.

Iobitridol is well tolerated after intraarterial administration and it has the same diagnostic quality as iopromide and iopamidol.